Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia Zyvox

Executive Summary

Submission to FDA of cases of suspected vancomycin-resistant Enterococcus faecium resistant to linezolid will likely show a lower frequency of documented cases of resistance than reported in an April 14 article in The Lancet. In the 45-patient study, one patient (2.2%) had documented resistance to linezolid in VRE. Pharmacia's reports to FDA will include patients from clinical trials and compassionate-use programs. The company intends to file for the treatment of infections due to penicillin-resistant Streptococcus pneumoniae at the end of 2001 or early 2002
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel